Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.01 Insider Own- Shs Outstand32.85M Perf Week-5.36%
Market Cap205.05M Forward P/E- EPS next Y-2.28 Insider Trans- Shs Float- Perf Month23.85%
Income-65.98M PEG- EPS next Q- Inst Own2.85% Short Float- Perf Quarter58.46%
Sales7.63M P/S26.87 EPS this Y1.86% Inst Trans-0.92% Short Ratio2.85 Perf Half Y41.10%
Book/sh5.69 P/B1.09 EPS next Y-10.98% ROA-27.85% Short Interest0.09M Perf Year-6.51%
Cash/sh5.83 P/C1.06 EPS next 5Y- ROE-30.67% 52W Range3.32 - 12.70 Perf YTD47.85%
Dividend Est.- P/FCF- EPS past 5Y-3.32% ROI-34.82% 52W High-51.34% Beta1.04
Dividend TTM- Quick Ratio14.68 Sales past 5Y342.86% Gross Margin- 52W Low86.14% ATR (14)0.68
Dividend Ex-Date- Current Ratio14.68 EPS Y/Y TTM-28.75% Oper. Margin-915.03% RSI (14)48.12 Volatility5.61% 9.15%
Employees182 Debt/Eq0.02 Sales Y/Y TTM-63.16% Profit Margin-864.47% Recom3.00 Target Price8.56
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q19.67% Payout- Rel Volume0.86 Prev Close6.70
Sales Surprise13.43% EPS Surprise7.44% Sales Q/Q-5.01% EarningsMar 14 AMC Avg Volume30.28K Price6.18
SMA20-14.42% SMA5018.44% SMA20030.91% Trades Volume25,976 Change-7.76%
Date Action Analyst Rating Change Price Target Change
Aug-30-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-29-22Downgrade SVB Leerink Outperform → Mkt Perform $30 → $8
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Today 12:16PM
Jun-24-24 07:16AM
Jun-20-24 07:28AM
Jun-17-24 01:00AM
Jun-14-24 07:30AM
01:00AM Loading…
Jun-12-24 07:46AM
Jun-11-24 01:00AM
Jun-01-24 08:00AM
May-16-24 04:00PM
Apr-29-24 11:00AM
Apr-19-24 11:12AM
Apr-17-24 11:12AM
Mar-26-24 09:26AM
Mar-14-24 04:00PM
04:00PM Loading…
Mar-01-24 04:00PM
Jan-07-24 04:00PM
Jan-05-24 04:00PM
Dec-14-23 01:00AM
Dec-10-23 12:00PM
Nov-14-23 01:00AM
Nov-03-23 12:00PM
Nov-02-23 02:00AM
Nov-01-23 02:00AM
Oct-26-23 04:00PM
Sep-13-23 01:00AM
Aug-24-23 04:00PM
Jul-13-23 08:06AM
Jun-27-23 01:00AM
Jun-19-23 12:00PM
08:59AM Loading…
Jun-02-23 08:59AM
May-25-23 05:01PM
May-16-23 04:00PM
May-13-23 02:00AM
May-11-23 04:00PM
Apr-18-23 01:44AM
Apr-14-23 01:00AM
Apr-04-23 11:44AM
Mar-13-23 09:30AM
Mar-11-23 02:14AM
Mar-09-23 04:00PM
Mar-02-23 04:00PM
Feb-28-23 01:15AM
Feb-10-23 01:00AM
Jan-16-23 01:00AM
Jan-12-23 06:18AM
Jan-08-23 03:00PM
Dec-30-22 01:00AM
Dec-12-22 07:00PM
Dec-01-22 11:46PM
Nov-10-22 01:00AM
Nov-04-22 09:39AM
Nov-03-22 12:30PM
Nov-02-22 12:30PM
Oct-27-22 04:00PM
Aug-25-22 04:30PM
Aug-18-22 01:00AM
Jul-21-22 11:30AM
Jun-10-22 01:00AM
May-12-22 04:05PM
May-11-22 01:00AM
May-03-22 12:00PM
Apr-27-22 08:02AM
Apr-26-22 04:05PM
Apr-23-22 01:00AM
Apr-13-22 12:00PM
Mar-24-22 02:00AM
Mar-17-22 01:00AM
Mar-15-22 04:30PM
Feb-25-22 04:30PM
Feb-11-22 04:10PM
Feb-10-22 07:13AM
Jan-28-22 05:57AM
Jan-23-22 02:28AM
Jan-18-22 01:00AM
Jan-13-22 05:00PM
Jan-12-22 10:13AM
Jan-11-22 11:37AM
Jan-10-22 06:51PM
Jan-06-22 10:00AM
Jan-05-22 04:05PM
Dec-15-21 01:00AM
Dec-14-21 12:16PM
Dec-12-21 04:00PM
Dec-09-21 01:00AM
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.